SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today celebrates its 10th anniversary, marking a decade of transforming how healthcare teams deliver care for patients. The company launched in 2016 to solve a key problem: variability in healthcare means that many patients fail to get guideline based care, even in life threatening diseases like stroke. Since achieving the first FDA clearance for an AI platform and increasing tr
Financial
Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Michael H. Carrel to its Board of Directors
Board appointment adds proven medical device leadershipMINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the appointment of seasoned medical device executive Michael H. Carrel to its Board of Directors effective July 20. “We are pleased to welcome Mr. Carrel to our Board of Directors,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “Mike brings extensive executive leadership, board and medical device experience, including a strong track record of developing and commercializing minimally invasive therapies, and we look forward to his guidance as we continue advancing Inspire therapy for the many patients affected by OSA.” Mr. Carrel has served as President, Chief Executive Officer, and a director of AtriCure, Inc. (NASDAQ: ATRC), an innovative cardiac device company, since November 2012. Under Mr. Carrel’s leadership, AtriCure has advanced a robust pipeline of novel products for the treatment of atrial fibrillation, left atrial appendage management and pain management. During his tenure, AtriCure has grown from $82 million in revenue in 2013 to $535 million in 2025 while helping more than one million patients. Previously, Mr. Carrel served as Chairman of the Board of Directors of Axonics, Inc. from 2019 through 2024, until its sale to Boston Scientific Corporation. Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School of the University of Pennsylvania. “I am excited to join Inspire at this important stage in the Company’s growth,” said Mr. Carrel. “With the recent launch of the fifth-generation Inspire device, a compelling product pipeline and a growing body of evidence demonstrating the long-term benefits of Inspire therapy, particularly in cardiovascular health, I believe the Company is well positioned to continue expanding access to care for patients with OSA.” About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA-, EU MDR- and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com. Investor and Media ContactEzgi YagciVice President, Investor Relationsezgiyagci@inspiresleep.com617-549-2443
CIRCA Scientific Appoints Jack Darby as Chief Executive Officer to Accelerate Commercial Expansion of Cardiovascular Access Portfolio
Veteran cardiovascular medical device executive to lead Company’s next phase of growth as CIRCA builds a differentiated cardiovascular access portfolio; Lee Geist transitions to Chief Operating Officer ENGLEWOOD, Colo., July 24, 2026 /PRNewswire/ — CIRCA Scientific, Inc., a…
Magnendo Secures $18M Series A Financing to Transform Endovascular Access for Stroke Intervention
MIT spinout to accelerate product development and first-in-human studies of its magnetic robotic navigation platform designed to dramatically improve the s
Wellumio closes oversubscribed $9.75 million pre-Series A round to accelerate portable stroke imaging technology
Australian medtech investor Bioshore Ventures and US neurotechnology investor Jumpspace Ventures join Wellumio’s oversubscribed pre-Series A round in the final close, supporting the next phase of clinical validation and commercialisation WELLINGTON, New Zealand, July 24, 2026 – Wellumio, a New Zealand medical technology company developing Axana®, a portable brain imaging […]
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5% Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5% Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies Q2 EPS of $0.421; adjusted2 EPS of $0.781 Recent clinical data at New York Valves reinforce best-in-clas
AtriCure Reports Second Quarter 2026 Financial Results
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their valu
Caristo Diagnostics Expands Executive Team, Naming David Vort Chief Commercial Officer and Chris Louk Chief Financial Officer
Appointments to scale adoption of Caristo’s AI-powered cardiovascular technologies globally OXFORD, England and STAMFORD, Conn., July 23, 2026 /PRNewswire/ — Caristo Diagnostics, a global leader in AI-powered technologies for cardiovascular disease, today announced two additions to its…
Xenter Closes Series B Financing, Raising $58.25 Million to Accelerate Commercial Expansion of its TechMed™ Platform
DRAPER, Utah— July 15, 2026 — Xenter, Inc., the world’s first TechMed™ company that has developed a healthcare intelligence platform for diagnostic evaluation and wireless medical devices that captures Physical Intelligence™ (PI) data over the XenFi™ wireless ecosystem, today announced the successful close on June 30th of its Series B financing, raising a […]
Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.



